结肠癌肝转移灶68Ga-PSMA摄取而FDG PET未显示
本文报告一例74岁男性结肠癌并新诊断前列腺癌患者,肝转移灶在初始FDG PET阳性,后续治疗后FDG PET失去摄取,而68Ga-PSMA PET显示摄取,活检证实为结肠来源转移。提示PSMA在多种肿瘤新生血管中表达,未来可能作为诊疗一体化药物新应用。
要点
- 结肠癌肝转移灶在治疗后FDG PET上失去摄取,但68Ga-PSMA PET显示摄取。
- PSMA-avid肝病灶活检证实为结肠来源转移。
- PSMA在前列腺癌以外的多种肿瘤新生血管中表达,未来可能作为诊疗一体化药物新应用。
核心结论
- 结肠癌肝转移灶可在治疗后FDG PET上失去摄取而68Ga-PSMA PET显示摄取,活检证实为结肠来源转移。
- PSMA在前列腺癌以外的多种肿瘤新生血管中表达,未来可能作为诊疗一体化药物新应用。
研究设计与样本
- 本文为病例报告,报告一例74岁男性结肠癌并新诊断前列腺癌患者。
主要发现
- 肝转移灶在初始FDG PET上为阳性,在后续治疗后FDG PET扫描上失去FDG摄取。
- 68Ga-PSMA PET显示肝转移灶摄取,活检证实为结肠来源转移。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
18 F-FDG PET/CT scan is a well-known modality to assess distant metastases and treatment response in the patients with primary colon cancer. We are presenting an interesting case of 68 Ga-PSMA-avid liver metastases in a 74-year-old man with colon cancer and recently diagnosed prostate cancer. The liver metastases were positive on initial FDG PET but lost FDG avidity on subsequent posttreatment FDG PET scans. Biopsy from the PSMA-avid liver lesions confirmed metastasis from colon origin. PSMA is expressed in various forms of tumor neovasculature other than prostate cancer with potential new applications as a theranostic agent in the future.
引用
- Doroudinia A, Chekuri S. 68 Ga-PSMA-Avid Liver Metastases From Colon Cancer, Not Visualized on FDG PET Scan. Clin Nucl Med. 2023. PMID: 37756469. doi:10.1097/RLU.0000000000004850
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。